Who are levofloxacin; metronidazole's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levofloxacin-metronidazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

levofloxacin; metronidazole — Competitive Intelligence Brief

levofloxacin; metronidazole (levofloxacin; metronidazole) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone + Nitroimidazole combination antibiotic. Area: Infectious Disease.

marketed Fluoroquinolone + Nitroimidazole combination antibiotic Bacterial DNA gyrase, topoisomerase IV (levofloxacin); bacterial DNA (metronidazole) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

levofloxacin; metronidazole (levofloxacin; metronidazole) — Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. This combination uses levofloxacin (a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV) and metronidazole (a nitroimidazole that damages bacterial DNA) to provide broad-spectrum anaerobic and aerobic bacterial coverage.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
levofloxacin; metronidazole TARGET	levofloxacin; metronidazole	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	marketed	Fluoroquinolone + Nitroimidazole combination antibiotic	Bacterial DNA gyrase, topoisomerase IV (levofloxacin); bacterial DNA (metronidazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone + Nitroimidazole combination antibiotic class)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). levofloxacin; metronidazole — Competitive Intelligence Brief. https://druglandscape.com/ci/levofloxacin-metronidazole. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab